05/15/2017
Anapharm Europe Announces Rebranding & Laboratory Expansion
We are pleased to announce that as part of our rebranding strategy, our brand name has now changed from Anapharm Europe to Anapharm Bioanalytics.
Our rebranding project is built on many improvements we have made to our services as well as on the international growth of our business. We have recently completed the expansion of our facilities in Barcelona increasing our lab space by 50%, acquired two additional ABSciex 6500 LC-MS/MS/UPLC platforms, upgraded software and hired additional staff in order to offer our clients increased capacity and improved study timelines for both small and large molecule bioanalysis.
The name change does not affect the legal personality of the existing entity (namely Anapharm Europe S.L.U.) which retains its rights and obligations in all existing legal relationships with third parties as well as the regulatory track record achieved to date including GLP and ANVISA certifications as well as FDA and EU-GCP inspection history.
What it means for our clients is that it is business as usual. We will continue to execute projects with the same, if not better, level of excellence and quality standards you have come to experience.
Our e-mail addresses will change but our phone numbers and headquarter’s address will remain the same. You can continue to connect with us online at our new website www.anapharmbioanalytics.com.
We take this opportunity to thank all our valued clients for their continued trust and look forward to delivering great value services that meet your expectations time after time.
MORE NEWS
Challenges in the Development of a Method for the Detection of Anti-PEGylated-aptamer Antibodies
Immunogenicity assays capable of properly determining the presence of anti-drug antibodies (ADA) and anti-PEG antibodies have been recognized of great importance due to the fact that pre-existing anti-PEG antibodies could have an impact on the efficacy of a drug coupled to polyethylene glycol (PEG).
READ MOREChallenges in the determination of two analytes with different physicochemical properties, Tapinarof and its main metabolite, Tapinarof Sulfate, at the low picogram level
The challenge of developing a new bioanalytical method considerably increases when two or more metabolites need to be simultaneously analysed. Their extraction and chromatography optimization can be further complicated if their physicochemical properties vary significantly. Method development may be even more difficult when low limits of quantitation are required, for instance, when evaluating the systemic adsorption of topical drugs.
READ MOREAnapharm Bioanalytics Brazilian ANVISA Certificate Renewal
Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2024.
READ MORE